🇺🇸 FDA
Patent

US 9314477

Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof

granted A61KA61K31/395A61K31/435

Quick answer

US patent 9314477 (Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof) held by RedHill Biopharma Ltd. expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RedHill Biopharma Ltd.
Grant date
Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/395, A61K31/435, A61K31/438, A61K31/44